Cargando…

Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study

OBJECTIVE: The aim of this study was to quantitatively evaluate the efficacy of a self-monitoring intervention for the management of persistent chemotherapy-induced peripheral neuropathy (CIPN). METHODS: A randomized controlled clinical trial was conducted on 65 outpatients receiving taxane or plati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Kiyoko, Ishida, Kazuko, Kyota, Ayumi, Ishihara, Chiaki, Fujimoto, Keiko, Hosokawa, Mai, Mochizuki, Ruka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025959/
https://www.ncbi.nlm.nih.gov/pubmed/36949819
http://dx.doi.org/10.1016/j.apjon.2023.100198
_version_ 1784909445696847872
author Kanda, Kiyoko
Ishida, Kazuko
Kyota, Ayumi
Ishihara, Chiaki
Fujimoto, Keiko
Hosokawa, Mai
Mochizuki, Ruka
author_facet Kanda, Kiyoko
Ishida, Kazuko
Kyota, Ayumi
Ishihara, Chiaki
Fujimoto, Keiko
Hosokawa, Mai
Mochizuki, Ruka
author_sort Kanda, Kiyoko
collection PubMed
description OBJECTIVE: The aim of this study was to quantitatively evaluate the efficacy of a self-monitoring intervention for the management of persistent chemotherapy-induced peripheral neuropathy (CIPN). METHODS: A randomized controlled clinical trial was conducted on 65 outpatients receiving taxane or platinum-based anticancer drugs. Participants were assigned to the control group (CG; n ​= ​32) or the self-monitoring group (SMG; n ​= ​33) and followed for 6 weeks. Non-interveners were blinded. Participants in the intervention group self-monitored and recorded. The researchers provided feedback on the recorded symptoms and coping strategies once every 3 weeks. The efficacy of the 6-week self-monitoring intervention was assessed, using various measures, at baseline (T0), 3 weeks (T1), and 6 weeks (T2). Scores of CIPN, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity, Distress and Impact Thermometer, Self–Efficacy Scale for Advanced Cancer, and Functional Assessment of Cancer Therapy-General of both groups were compared. Safety behavior in daily life was also compared. The study was conducted from August 9, 2017 to March 30, 2020 in outpatient clinics at three hospitals. Analysis was conducted using the t-test, Mann–Whitney U test, χ(2) test, and two-way repeated-measures analysis of variance (two-way RMANOVA). RESULTS: No significant differences were noted between the two groups in the CIPN score, the Distress and Impact Thermometer score, and in safety behavior in daily life. The mean Self-Efficacy Scale for Advanced Cancer score at T1 differed between the two groups (CG mean ​± ​SD: 358.44 ​± ​109.90; SMG mean ​± ​SD: 421.21 ​± ​85.54), which was significantly higher in the SMG (P ​= ​0.012). Two-way RMANOVA revealed an interaction between the CG and SMG (F ​= ​5.689, P ​= ​0.004). Quality of life scores were higher in the SMG than in the CG at T0, T1, and T2. Two-way RMANOVA analysis showed an effect of the intervention (F ​= ​7.914, P ​= ​0.007). CONCLUSIONS: The self-monitoring intervention maintained the participants’ quality of life. This finding suggests its effectiveness in patients with peripheral neuropathy.
format Online
Article
Text
id pubmed-10025959
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100259592023-03-21 Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study Kanda, Kiyoko Ishida, Kazuko Kyota, Ayumi Ishihara, Chiaki Fujimoto, Keiko Hosokawa, Mai Mochizuki, Ruka Asia Pac J Oncol Nurs Original Article OBJECTIVE: The aim of this study was to quantitatively evaluate the efficacy of a self-monitoring intervention for the management of persistent chemotherapy-induced peripheral neuropathy (CIPN). METHODS: A randomized controlled clinical trial was conducted on 65 outpatients receiving taxane or platinum-based anticancer drugs. Participants were assigned to the control group (CG; n ​= ​32) or the self-monitoring group (SMG; n ​= ​33) and followed for 6 weeks. Non-interveners were blinded. Participants in the intervention group self-monitored and recorded. The researchers provided feedback on the recorded symptoms and coping strategies once every 3 weeks. The efficacy of the 6-week self-monitoring intervention was assessed, using various measures, at baseline (T0), 3 weeks (T1), and 6 weeks (T2). Scores of CIPN, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity, Distress and Impact Thermometer, Self–Efficacy Scale for Advanced Cancer, and Functional Assessment of Cancer Therapy-General of both groups were compared. Safety behavior in daily life was also compared. The study was conducted from August 9, 2017 to March 30, 2020 in outpatient clinics at three hospitals. Analysis was conducted using the t-test, Mann–Whitney U test, χ(2) test, and two-way repeated-measures analysis of variance (two-way RMANOVA). RESULTS: No significant differences were noted between the two groups in the CIPN score, the Distress and Impact Thermometer score, and in safety behavior in daily life. The mean Self-Efficacy Scale for Advanced Cancer score at T1 differed between the two groups (CG mean ​± ​SD: 358.44 ​± ​109.90; SMG mean ​± ​SD: 421.21 ​± ​85.54), which was significantly higher in the SMG (P ​= ​0.012). Two-way RMANOVA revealed an interaction between the CG and SMG (F ​= ​5.689, P ​= ​0.004). Quality of life scores were higher in the SMG than in the CG at T0, T1, and T2. Two-way RMANOVA analysis showed an effect of the intervention (F ​= ​7.914, P ​= ​0.007). CONCLUSIONS: The self-monitoring intervention maintained the participants’ quality of life. This finding suggests its effectiveness in patients with peripheral neuropathy. Elsevier 2023-02-04 /pmc/articles/PMC10025959/ /pubmed/36949819 http://dx.doi.org/10.1016/j.apjon.2023.100198 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Kanda, Kiyoko
Ishida, Kazuko
Kyota, Ayumi
Ishihara, Chiaki
Fujimoto, Keiko
Hosokawa, Mai
Mochizuki, Ruka
Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study
title Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study
title_full Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study
title_fullStr Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study
title_full_unstemmed Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study
title_short Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study
title_sort randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: a quantitative study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025959/
https://www.ncbi.nlm.nih.gov/pubmed/36949819
http://dx.doi.org/10.1016/j.apjon.2023.100198
work_keys_str_mv AT kandakiyoko randomizedclinicaltrialquantifyingtheeffectivenessofaselfmonitoringinterventionincancerpatientswithperipheralneuropathyaquantitativestudy
AT ishidakazuko randomizedclinicaltrialquantifyingtheeffectivenessofaselfmonitoringinterventionincancerpatientswithperipheralneuropathyaquantitativestudy
AT kyotaayumi randomizedclinicaltrialquantifyingtheeffectivenessofaselfmonitoringinterventionincancerpatientswithperipheralneuropathyaquantitativestudy
AT ishiharachiaki randomizedclinicaltrialquantifyingtheeffectivenessofaselfmonitoringinterventionincancerpatientswithperipheralneuropathyaquantitativestudy
AT fujimotokeiko randomizedclinicaltrialquantifyingtheeffectivenessofaselfmonitoringinterventionincancerpatientswithperipheralneuropathyaquantitativestudy
AT hosokawamai randomizedclinicaltrialquantifyingtheeffectivenessofaselfmonitoringinterventionincancerpatientswithperipheralneuropathyaquantitativestudy
AT mochizukiruka randomizedclinicaltrialquantifyingtheeffectivenessofaselfmonitoringinterventionincancerpatientswithperipheralneuropathyaquantitativestudy